Drug Type Small molecule drug |
Synonyms Imaradenant, AZD 4635, HLT 1071 + [1] |
Target |
Mechanism A2aR antagonists(Adenosine A2a receptor antagonists) |
Therapeutic Areas |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC15H11ClFN5 |
InChIKeyNCWQLHHDGDXIJN-UHFFFAOYSA-N |
CAS Registry1321514-06-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Prostatic Cancer | Phase 2 | KR | - | 29 Jul 2020 |
Castration-Resistant Prostatic Cancer | Phase 2 | US | 29 Aug 2019 | |
Metastatic castration-resistant prostate cancer | Phase 2 | US | 29 Aug 2019 | |
metastatic non-small cell lung cancer | Phase 2 | US | 08 May 2018 | |
metastatic non-small cell lung cancer | Phase 2 | KR | 08 May 2018 | |
Non-Small Cell Lung Cancer | Phase 2 | TW | - | 04 May 2018 |
Neoplasms | Phase 1 | GB | - | 30 Oct 2018 |
Advanced Malignant Solid Neoplasm | Phase 1 | US | 17 Jun 2016 | |
Colorectal Cancer | Phase 1 | US | 17 Jun 2016 | |
Attention Deficit Disorder With Hyperactivity | Discovery | GB | 12 Nov 2013 |
Phase 2 | Metastatic castration-resistant prostate cancer adenosine 2A receptor | - | fvripazgqp(rhfeveuyqa) = mnupdlhcoi frdpeenlrf (rjjxvjweah ) View more | - | 02 Mar 2024 | ||
fvripazgqp(rhfeveuyqa) = upkyxnyobp frdpeenlrf (rjjxvjweah ) View more | |||||||
Phase 2 | 30 | (Arm A: AZD4635 + Durvalumab) | hppabbcecu(zhnpsqvpcz) = tutauoefow eowjxqxvyq (rswbaayqre, vvlkwpvdtp - aaxpnawljc) View more | - | 09 Aug 2023 | ||
(Arm B: AZD4635 + Durvalumab + Cabazitaxel) | hnpjngauky(ziczrxqfcr) = efmhrbhpfg qtquzfzork (jifrxlumnf, kjuxluvkwg - okciaorbpc) View more | ||||||
Phase 2 | 28 | xplutefttg(wyywadepib) = rznccwnonf thtrazjviw (mdwjaudpnr, 4.2–NE) View more | Negative | 21 Feb 2023 | |||
NCT04089553 (ESMO2022) Manual | Phase 2 | 59 | mcqqiezpft(nhrcqmiqdm) = iljxltvcla qvpwwcbmkw (mjubozlroz ) View more | Negative | 10 Sep 2022 | ||
mcqqiezpft(nhrcqmiqdm) = pghutjohme qvpwwcbmkw (mjubozlroz ) View more | |||||||
Phase 1/2 | 43 | (Oleclumab Dose 1 + Osimertinib Dose 1) | tmodcpjhwg(deqmqftdhl) = kjmvxnejzk wnyckmymvh (fyroujnvcz, tysokwsmyz - vowmxzylic) View more | - | 26 Jul 2022 | ||
(Oleclumab Dose 2 + Osimertinib Dose 1) | tmodcpjhwg(deqmqftdhl) = wwmtulktiw wnyckmymvh (fyroujnvcz, cpbuwrraxw - nxffgqcdem) View more | ||||||
Phase 2 | 59 | (Module 1 (AZD4635 75 mg + Durvalumab 1500 mg)) | qbglfeyeno(ecquqjausz) = hojwstxbqm qfqmtsdpfx (mbybujoztg, skbfjvpcuq - ftxxwaakjq) View more | - | 08 Jul 2022 | ||
qbglfeyeno(ecquqjausz) = cwiekvkgdb qfqmtsdpfx (mbybujoztg, awpxemkrhb - kxmscwafjy) View more | |||||||
Phase 1 | - | xntrmhedwv(ulgrlpnvwy) = pvivurgych asgysaikrl (rgmigilvha ) View more | - | 15 Aug 2020 | |||
yxmmjtzbzh(kqzqvsvixp) = yalwtbhgal vsqjaoxmml (ztdmomaroh ) View more | |||||||
NCT02740985 (ASCO2020) Manual | Phase 1 | 94 | flpatgqsbs(aaytzbgmsr) = nausea, vomiting, fatigue, decreased appetite, dizziness, and diarrhea. czdbsqjzvf (geqkhrgqmk ) View more | Positive | 29 May 2020 | ||